SGLT2 Inhibitors for Adult Congenital Heart Disease
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 400 (estimated)
- Sponsor
- Leiden University Medical Center · Other
This trial is looking for adults with congenital heart defects who have started treatment with SGLT2 inhibitors. Participation involves allowing researchers to collect data on how these drugs affect heart health and safety.
You may be able to join if
- I have a congenital heart defect.
- I am 18 years or older.
- I have started treatment with an SGLT2 inhibitor.
You may not be able to join if
- I did not give consent for data collection.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Loading trial locations…